Collaboration and License Agreements (Details) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended			9 Months Ended		12 Months Ended	15 Months Ended	33 Months Ended
	Feb. 28, 2015 USD ($)	Jul. 31, 2006 USD ($) $ / shares shares	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Sep. 30, 2014 USD ($)	Sep. 30, 2015 USD ($) item	Sep. 30, 2014 USD ($)	Jun. 30, 2015 USD ($)	Sep. 30, 2011	Mar. 31, 2015
Collaboration revenues:
Product revenue			$ 8,666		$ 4,714	$ 30,693	$ 15,216
Research and development revenue
Regulatory and commercial milestones						20,000
Amortization of upfront payments			2,442		888	6,572	2,789
Research and development services (FTEs) and external costs			2,687		3,734	9,993	13,066
Total research and development revenue			5,129		4,622	36,565	15,855
Total collaboration revenue			13,795		9,336	67,258	31,071
Operating expenses:
Research and Development Expense			525		4,133	2,287	12,975
General and Administrative Expense			308		341	1,273	824
Total Operating expenses			833		4,474	3,560	13,799
2003 Sandoz Collaboration
Collaboration revenues:
Product revenue					4,714	2,843	15,216
Research and development revenue
Research and development services (FTEs) and external costs			69		195	450	796
Total research and development revenue			69		195	450	796
Total collaboration revenue			69		4,909	3,293	16,012
Operating expenses:
Research and Development Expense					50	208	134
General and Administrative Expense			104		15	326	110
Total Operating expenses			104		65	$ 534	244
Percentage of contractual profits earned under collaborative arrangement									45.00%
Percentage of royalty for net sales up to pre-defined sales threshold										10.00%
Percentage of royalty for net sales above pre-defined sales threshold										12.00%
Percentage of royalty based on contractually defined profits on sales						50.00%
Maximum percentage of reduction of profit-share, royalty and milestone payments from Sandoz at each quarter						50.00%
Payment of total annual adjustment through reduction in product revenue				$ 100
Reduction in product revenue due to netting of shared development and other expenses								$ 1,900
Collaborative Arrangement, carry forward to future periods						$ 1,800
Number of significant deliverables identified in arrangement | item						2
Second Sandoz Collaboration Agreement
Collaboration revenues:
Product revenue			8,666			$ 27,850
Research and development revenue
Regulatory and commercial milestones						20,000
Amortization of upfront payments					121		480
Research and development services (FTEs) and external costs			742		944	2,220	1,738
Total research and development revenue			742		1,065	22,220	2,218
Total collaboration revenue			9,408		1,065	50,070	2,218
Operating expenses:
Research and Development Expense			274		444	703	973
General and Administrative Expense			38		84	149	315
Total Operating expenses			312		528	$ 852	1,288
Percentage of royalty based on contractually defined profits on sales						50.00%
Profits recorded on sales			8,700			$ 36,900
Number of shares sold | shares		4,708,679
Per share price of shares sold | $ / shares		$ 15.93
Closing price of the company's common stock on the NASDAQ Global Market (in dollars per share) | $ / shares		$ 13.05
Aggregate purchase price of shares sold		$ 75,000
Premium paid		$ 13,600
Collaborative Arrangement, Legal Expenses						9,000
Second Sandoz Collaboration Agreement | Maximum
Operating expenses:
Milestone payments possible per agreement			143,000			143,000
Commercial milestone payments			10,000			10,000
Sales-based and commercial milestone payments possible per agreement			120,000			120,000
Sales-based and commercial milestone payments possible in European Union						23,000
Regulatory milestone payment earned						$ 10,000
Second Sandoz Collaboration Agreement | Novartis Pharma AG
Operating expenses:
Percentage of contractual profits earned under collaborative arrangement						50.00%
Baxalta Agreement
Research and development revenue
Amortization of upfront payments			2,442		767	$ 6,572	2,309
Research and development services (FTEs) and external costs			1,876		2,595	7,323	10,532
Total research and development revenue			4,318		3,362	13,895	12,841
Total collaboration revenue			4,318		3,362	13,895	12,841
Operating expenses:
Research and Development Expense			251		3,639	1,376	11,868
General and Administrative Expense			166		242	798	399
Total Operating expenses			417		$ 3,881	$ 2,174	$ 12,267
Number of independent companies completed restructuring activities | item						2
Number of additional biosimilars under the agreement | item						4
Upfront payment paid by Baxter to the company						$ 33,000
Option payments agreed to be paid by Baxter with respect to additional product candidates						12,000
Option payment which the entity is no longer eligible to receive						7,000
Remaining payment obligation			$ 0			$ 0
Baxalta Agreement | Accounting Standards Update 2009 to 2013 Member
Operating expenses:
Number of significant deliverables identified in arrangement | item						7
Total arrangement consideration						$ 61,000
Portion of revised arrangement consideration reallocated to the remaining deliverables	$ 40,000
Portion of revised arrangement consideration allocated to the first initial product license as a result of termination of product	39,600
Portion of revised arrangement consideration allocated to each of the three additional product licenses as a result of termination of product	$ 400
Decrease in portion of revised arrangement consideration reallocated to the remaining deliverables						$ 40,000
Estimate performance period for the joint steering committee						6 years
Number of follow-on biologic products for development and product licenses | item						2
Number of additional follow-on biologic products for development and product licenses | item						4
Number of additional follow-on biologic products for research and development services | item						4
Deferred revenue						$ 24,400
Deferred revenue included in current liabilities						9,800
Deferred revenue included in non-current liabilities						14,600
Baxalta Agreement | Maximum
Operating expenses:
Aggregate regulatory milestone to be paid by Baxter						$ (50,000)